Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017, 51293-51298 [2017-24009]

Download as PDF ethrower on DSK3G9T082PROD with NOTICES Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices (‘‘the ’557 patent’’). The complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders. ADDRESSES: The complaint, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205– 2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. FOR FURTHER INFORMATION CONTACT: Katherine Hiner, The Office of Secretary, Docket Services, U.S. International Trade Commission, telephone (202) 205–1802. SUPPLEMENTARY INFORMATION: Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2017). Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on October 30, 2017, Ordered that— (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain wafer-level packaging semiconductor devices and products containing same (including cellular phones, tablets, laptops, and notebooks) and components thereof by reason of infringement of one or more of claims 1–8 of the ’557 patent and claims 1–18 of the ’001 patent; and whether an industry in the United States exists as VerDate Sep<11>2014 16:18 Nov 02, 2017 Jkt 244001 required by subsection (a)(2) of section 337; (2) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served: (a) The complainant is: Tessera Advanced Technologies, Inc., 3025 Orchard Parkway, San Jose, CA 95134. (b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served: Samsung Electronics Co., Ltd., 129 Samsung-ro, Maetan-3dong, Yeongtonggu, Suwon-si, Gyeonggi-do, Republic of Korea 443–742. Samsung Electronics America, Inc., 85 Challenger Road, Ridgefield Park, NJ 07660. Samsung Semiconductor, Inc., 3655 N. 1st Street, San Jose, CA 95134. (3) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. The Office of Unfair Import Investigations will not participate as a party in this investigation. Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. By order of the Commission. PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 51293 Issued: October 31, 2017. Lisa R. Barton, Secretary to the Commission. [FR Doc. 2017–24004 Filed 11–2–17; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–470F] Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017 Drug Enforcement Administration (DEA), Department of Justice (DOJ). ACTION: Final order. AGENCY: This final order establishes the final adjusted 2017 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. SUMMARY: This order is applicable November 3, 2017. DATES: FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control Division, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: Legal Authority Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100. Background The DEA published the 2017 established aggregate production quotas for controlled substances in schedules I and II and for the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the Federal Register on October 5, 2016. 81 FR 69079. This notice stated that the E:\FR\FM\03NON1.SGM 03NON1 51294 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices Administrator would adjust, as needed, the established aggregate production quotas in 2017 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. The 2017 proposed adjusted aggregate production quotas for controlled substances in schedules I and II and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the Federal Register on August 4, 2017, (82 FR 36449) in consideration of the outlined criteria. All interested persons were invited to comment on or object to the proposed adjusted aggregate production quotas and assessment of annual needs on or before September 5, 2017. Comments Received Three DEA-registered entities submitted timely comments regarding a total of eleven schedule I and II controlled substances. Comments received proposed that the aggregate production quotas for amphetamine (for conversion), dihydrocodeine, diphenoxylate (for sale), heroin, levorphanol, lisdexamfetmine, methadone intermediate, noroxymorphone (for conversion), oripavine, oxycodone (for sale), and oxymorphone (for conversion) were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks. The DEA received 43 comments from non-DEA registered entities in response to the DEA’s August 4, 2017, press release for the proposed 2018 aggregate production quotas. The majority of these commenters expressed concerns about the 20 percent decrease to the production quotas of controlled substances. The DEA also received two comments from non-DEA registered entities suggesting that the rescheduling of marihuana would drastically reduce opioid use, misuse, and addiction. These 45 comments addressed issues that were outside the scope of this final order, and therefore are not relevant to the analysis involved in finalizing the 2017 aggregate production quotas. The DEA received no comments from DEA-registered or non-DEA registered entities for previously established values of the 2017 assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine. Analysis for Final Adjusted 2017 Aggregate Production Quotas and Assessment of Annual Needs In determining the final adjusted 2017 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments that are specifically relevant to this Final Order for calendar year 2017 along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13 in accordance with 21 U.S.C. 826(a), and other relevant factors including the 2016 year-end inventories, initial 2017 manufacturing and import quotas, 2017 export requirements, actual and projected 2017 sales, research and product development requirements, and additional applications received. Based on all of the above, the Administrator is adjusting the 2017 aggregate production quotas and assessment of annual needs for 4-Anilino-N-Phenethyl-4-Piperidine (ANPP), dihydrocodeine, ephedrine (for sale), fentanyl, hydrocodone (for sale), meperidine, methadone intermediate, morphine (for sale), opium (tincture), Oripavine, oxycodone (for sale), Oxymorphone (for conversion), Oxymorphone (for sale), phenylpropanolamine (for conversion), phenylpropanolamine (for sale), pseudoephedrine (for sale), tapentadol, and thiafentanil. This final order reflects those adjustments. Regarding diphenoxylate (for sale), heroin, levorphanol, and noroxymorphone (for conversion) the Administrator hereby determines that the proposed adjusted 2017 aggregate production quotas and assessment of annual needs for these substances and list I chemicals as published on August 4, 2017, (82 FR 36449) are sufficient to meet the current 2017 estimated medical, scientific, research, and industrial needs of the United States and to provide for adequate reserve stock. This final order establishes these aggregate production quotas at the same amounts as proposed. Pursuant to the above, the Administrator hereby finalizes the 2017 aggregate production quotas for the following schedule I and II controlled substances and the 2017 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Final revised 2017 quotas (g) Basic class ethrower on DSK3G9T082PROD with NOTICES Schedule I 1-(1-Phenylcyclohexyl)pyrrolidine ...................................................................................................................................................... 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .......................................................................................................................... 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ......................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................................................. 1-Benzylpiperazine ............................................................................................................................................................................ 1-Methyl-4-phenyl-4-propionoxypiperidine ......................................................................................................................................... 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ......................................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ...................................................................................................................... 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ........................................................................................................................ 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) .................................................................................................................... 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ..................................................................................................................................... 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ...................... 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ...................................................................................................................... 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ...................... 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ............................................................................................................................ 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C-I–NBOMe; 25I; Cimbi-5) .............................. 2,5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................................................... 2,5-Dimethoxy-4-n-propylthiophenethylamine ................................................................................................................................... 2,5-Dimethoxyamphetamine .............................................................................................................................................................. 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) .............................................................................................................. 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ........................................................................................................ 3,4,5-Trimethoxyamphetamine .......................................................................................................................................................... 3,4-Methylenedioxyamphetamine (MDA) .......................................................................................................................................... VerDate Sep<11>2014 16:18 Nov 02, 2017 Jkt 244001 PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 E:\FR\FM\03NON1.SGM 03NON1 10 30 30 15 25 2 30 30 30 30 30 25 30 25 30 30 25 25 25 30 30 25 55 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices Final revised 2017 quotas (g) ethrower on DSK3G9T082PROD with NOTICES Basic class 3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................................................... 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ........................................................................................................................... 3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................................................ 3,4-Methylenedioxypyrovalerone (MDPV) ......................................................................................................................................... 3-FMC; 3-Fluoro-N-methylcathinone ................................................................................................................................................. 3-Methylfentanyl ................................................................................................................................................................................. 3-Methylthiofentanyl ........................................................................................................................................................................... 4-Bromo-2,5-dimethoxyamphetamine (DOB) .................................................................................................................................... 4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ............................................................................................................................... 4-Fluoroisobutyryl fentanyl ................................................................................................................................................................. 4-FMC; Flephedrone .......................................................................................................................................................................... 4-MEC; 4-Methyl-N-ethylcathinone .................................................................................................................................................... 4-Methoxyamphetamine .................................................................................................................................................................... 4-Methyl-2,5-dimethoxyamphetamine (DOM) .................................................................................................................................... 4-Methylaminorex .............................................................................................................................................................................. 4-Methyl-N-methylcathinone (mephedrone) ...................................................................................................................................... 4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ............................................................................................................................. 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ....................................................................................................... 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ......................... 5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .......................... 5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ................................................................. 5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ...................................................... 5-Fluoro-PB-22; 5F-PB-22 ................................................................................................................................................................. 5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .......................................... 5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................................................... 5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................................................ 5-Methoxy-N,N-dimethyltryptamine ................................................................................................................................................... AB-CHMINACA .................................................................................................................................................................................. AB-FUBINACA ................................................................................................................................................................................... AB-PINACA ........................................................................................................................................................................................ Acetyl Fentanyl .................................................................................................................................................................................. Acetyl-alpha-methylfentanyl ............................................................................................................................................................... Acetyldihydrocodeine ......................................................................................................................................................................... Acetylmethadol .................................................................................................................................................................................. ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ................................ ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .................................................... AH-7921 ............................................................................................................................................................................................. Allylprodine ........................................................................................................................................................................................ Alphacetylmethadol ............................................................................................................................................................................ alpha-Ethyltryptamine ........................................................................................................................................................................ Alphameprodine ................................................................................................................................................................................. Alphamethadol ................................................................................................................................................................................... alpha-Methylfentanyl .......................................................................................................................................................................... alpha-Methylthiofentanyl .................................................................................................................................................................... alpha-Methyltryptamine (AMT) .......................................................................................................................................................... alpha-Pyrrolidinobutiophenone (a-PBP) ............................................................................................................................................ alpha-Pyrrolidinopentiophenone (a-PVP) .......................................................................................................................................... Aminorex ............................................................................................................................................................................................ APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ....................................................................................... Benzylmorphine ................................................................................................................................................................................. Betacetylmethadol ............................................................................................................................................................................. beta-Hydroxy-3-methylfentanyl .......................................................................................................................................................... beta-Hydroxyfentanyl ......................................................................................................................................................................... beta-Hydroxythiofentanyl ................................................................................................................................................................... Betameprodine ................................................................................................................................................................................... Betamethadol ..................................................................................................................................................................................... Betaprodine ........................................................................................................................................................................................ Bufotenine .......................................................................................................................................................................................... Butylone ............................................................................................................................................................................................. Butyryl Fentanyl ................................................................................................................................................................................. Cathinone ........................................................................................................................................................................................... Codeine Methylbromide ..................................................................................................................................................................... Codeine-N-oxide ................................................................................................................................................................................ Desomorphine .................................................................................................................................................................................... Diethyltryptamine ............................................................................................................................................................................... Difenoxin ............................................................................................................................................................................................ Dihydromorphine ................................................................................................................................................................................ Dimethyltryptamine ............................................................................................................................................................................ Dipipanone ......................................................................................................................................................................................... Etorphine ............................................................................................................................................................................................ Fenethylline ........................................................................................................................................................................................ Furanyl Fentanyl ................................................................................................................................................................................ VerDate Sep<11>2014 16:18 Nov 02, 2017 Jkt 244001 PO 00000 Frm 00086 Fmt 4703 51295 Sfmt 4703 E:\FR\FM\03NON1.SGM 03NON1 50 40 40 35 25 30 30 25 25 30 25 25 150 25 25 45 25 50 40 30 30 30 20 25 25 25 25 30 50 30 100 30 30 2 30 50 30 2 2 25 2 2 30 30 25 25 25 25 25 30 2 30 30 30 2 4 2 3 25 30 24 30 330 25 25 8,750 1,566,000 35 5 30 30 30 51296 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices Final revised 2017 quotas (g) Basic class gamma-Hydroxybutyric acid .............................................................................................................................................................. Heroin ................................................................................................................................................................................................ Hydromorphinol .................................................................................................................................................................................. Hydroxypethidine ............................................................................................................................................................................... Ibogaine ............................................................................................................................................................................................. JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) .................................................................................................................... JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ......................................................................................................................................... JWH-073 (1-Butyl-3-(1-naphthoyl)indole) .......................................................................................................................................... JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) ..................................................................................................................... JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) ......................................................................................................................... JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ............................................................................................................. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .......................................................................................................................... JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ...................................................................................................................... JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) .......................................................................................................................... Lysergic acid diethylamide (LSD) ...................................................................................................................................................... MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3carboxamide) .................................................................................................................................................................................. MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ............... MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ......................................... Marihuana .......................................................................................................................................................................................... Mecloqualone ..................................................................................................................................................................................... Mescaline ........................................................................................................................................................................................... Methaqualone .................................................................................................................................................................................... Methcathinone ................................................................................................................................................................................... Methyldesorphine ............................................................................................................................................................................... Methyldihydromorphine ...................................................................................................................................................................... Morphine methylbromide ................................................................................................................................................................... Morphine methylsulfonate .................................................................................................................................................................. Morphine-N-oxide .............................................................................................................................................................................. N,N-Dimethylamphetamine ................................................................................................................................................................ Naphyrone ......................................................................................................................................................................................... N-Ethyl-1-phenylcyclohexylamine ...................................................................................................................................................... N-Ethylamphetamine ......................................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................................................... Noracymethadol ................................................................................................................................................................................. Norlevorphanol ................................................................................................................................................................................... Normethadone ................................................................................................................................................................................... Normorphine ...................................................................................................................................................................................... para-Fluorofentanyl ............................................................................................................................................................................ Parahexyl ........................................................................................................................................................................................... PB-22; QUPIC ................................................................................................................................................................................... Pentedrone ........................................................................................................................................................................................ Pentylone ........................................................................................................................................................................................... Phenomorphan .................................................................................................................................................................................. Pholcodine ......................................................................................................................................................................................... Psilocybin ........................................................................................................................................................................................... Psilocyn .............................................................................................................................................................................................. SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ......................................................................................... SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) ............................................................................................................ Tetrahydrocannabinols ...................................................................................................................................................................... Thiofentanil ........................................................................................................................................................................................ THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) .................................................................................. Tilidine ................................................................................................................................................................................................ Trimeperidine ..................................................................................................................................................................................... U-47700 ............................................................................................................................................................................................. UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................................... 56,200,000 45 2 2 30 35 45 45 30 30 35 30 30 30 40 30 30 30 472,000 30 25 60 25 5 2 5 5 350 25 25 5 24 24 2 55 2 40 25 5 20 25 25 2 5 30 50 45 30 409,000 25 30 25 2 30 25 ethrower on DSK3G9T082PROD with NOTICES Schedule II 1-Phenylcyclohexylamine .................................................................................................................................................................. 1-Piperidinocyclohexanecarbonitrile .................................................................................................................................................. 4-Anilino-N-phenethyl-4-piperidine (ANPP) ....................................................................................................................................... Alfentanil ............................................................................................................................................................................................ Alphaprodine ...................................................................................................................................................................................... Amobarbital ........................................................................................................................................................................................ Amphetamine (for conversion) .......................................................................................................................................................... Amphetamine (for sale) ..................................................................................................................................................................... Carfentanil .......................................................................................................................................................................................... Cocaine .............................................................................................................................................................................................. Codeine (for conversion) ................................................................................................................................................................... Codeine (for sale) .............................................................................................................................................................................. Dextropropoxyphene .......................................................................................................................................................................... VerDate Sep<11>2014 16:18 Nov 02, 2017 Jkt 244001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\03NON1.SGM 03NON1 4 4 1,050,000 4,200 2 20,100 12,000,000 42,400,000 20 103,400 40,000,000 45,000,000 35 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 51297 Final revised 2017 quotas (g) Basic class Dihydrocodeine .................................................................................................................................................................................. Dihydroetorphine ................................................................................................................................................................................ Diphenoxylate (for conversion) .......................................................................................................................................................... Diphenoxylate (for sale) ..................................................................................................................................................................... Ecgonine ............................................................................................................................................................................................ Ethylmorphine .................................................................................................................................................................................... Etorphine Hydrochloride .................................................................................................................................................................... Fentanyl ............................................................................................................................................................................................. Glutethimide ....................................................................................................................................................................................... Hydrocodone (for conversion) ........................................................................................................................................................... Hydrocodone (for sale) ...................................................................................................................................................................... Hydromorphone ................................................................................................................................................................................. Isomethadone .................................................................................................................................................................................... Levo-alphacetylmethadol (LAAM) ...................................................................................................................................................... Levomethorphan ................................................................................................................................................................................ Levorphanol ....................................................................................................................................................................................... Lisdexamfetamine .............................................................................................................................................................................. Meperidine ......................................................................................................................................................................................... Meperidine Intermediate-A ................................................................................................................................................................ Meperidine Intermediate-B ................................................................................................................................................................ Meperidine Intermediate-C ................................................................................................................................................................ Metazocine ......................................................................................................................................................................................... Methadone (for sale) ......................................................................................................................................................................... Methadone Intermediate .................................................................................................................................................................... Methamphetamine ............................................................................................................................................................................. 360,000 2 15,000 1,110,000 99,000 30 32 1,350,000 2 122,000 51,900,000 5,140,800 30 5 30 12,900 19,000,000 2,904,000 5 30 5 15 23,700,000 28,700,000 1,539,100 [900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)] Methylphenidate ................................................................................................................................................................................. Morphine (for conversion) .................................................................................................................................................................. Morphine (for sale) ............................................................................................................................................................................ Nabilone ............................................................................................................................................................................................. Noroxymorphone (for conversion) ..................................................................................................................................................... Noroxymorphone (for sale) ................................................................................................................................................................ Opium (powder) ................................................................................................................................................................................. Opium (tincture) ................................................................................................................................................................................. Oripavine ............................................................................................................................................................................................ Oxycodone (for conversion) .............................................................................................................................................................. Oxycodone (for sale) ......................................................................................................................................................................... Oxymorphone (for conversion) .......................................................................................................................................................... Oxymorphone (for sale) ..................................................................................................................................................................... Pentobarbital ...................................................................................................................................................................................... Phenazocine ...................................................................................................................................................................................... Phencyclidine ..................................................................................................................................................................................... Phenmetrazine ................................................................................................................................................................................... Phenylacetone ................................................................................................................................................................................... Racemethorphan ............................................................................................................................................................................... Racemorphan .................................................................................................................................................................................... Remifentanil ....................................................................................................................................................................................... Secobarbital ....................................................................................................................................................................................... Sufentanil ........................................................................................................................................................................................... Tapentadol ......................................................................................................................................................................................... Thiafentanil ........................................................................................................................................................................................ Thebaine ............................................................................................................................................................................................ 73,000,000 27,300,000 35,000,000 19,000 17,700,000 400,000 90,000 500,000 28,900,000 2,610,000 101,500,000 23,000,000 3,600,000 27,500,000 5 35 25 40 5 5 3,000 172,002 4,000 18,600,000 30 100,000,000 ethrower on DSK3G9T082PROD with NOTICES List I Chemicals Ephedrine (for conversion) ................................................................................................................................................................ Ephedrine (for sale) ........................................................................................................................................................................... Phenylpropanolamine (for conversion) .............................................................................................................................................. Phenylpropanolamine (for sale) ......................................................................................................................................................... Pseudoephedrine (for conversion) .................................................................................................................................................... Pseudoephedrine (for sale) ............................................................................................................................................................... VerDate Sep<11>2014 16:18 Nov 02, 2017 Jkt 244001 PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 E:\FR\FM\03NON1.SGM 03NON1 50,000 4,810,000 13,600,000 7,000,000 40 186,000,000 51298 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices Aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Dated: October 27, 2017. Robert W. Patterson, Acting Administrator. [FR Doc. 2017–24009 Filed 11–2–17; 8:45 am] BILLING CODE 4410–09–P Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on March 17, 2017, Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816 applied to be registered as an importer the following basic classes of controlled substances: DEPARTMENT OF JUSTICE Controlled substance Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Rhodes Technologies ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 4, 2017. Such persons may also file a written request for a hearing on the application on or before December 4, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007). SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant ethrower on DSK3G9T082PROD with NOTICES DATES: VerDate Sep<11>2014 16:18 Nov 02, 2017 Jkt 244001 Drug code Tetrahydrocannabinols. Methylphenidate Oxycodone ....... Hydromorphone Hydrocodone .... Morphine ........... Oxymorphone ... Opium, raw ....... Poppy Straw Concentrate. Schedule 7370 I 1724 9143 9150 9193 9300 9652 9600 9670 II II II II II II II II The company plans to import opium, raw (9600) and poppy straw concentrate (9670) in order to bulk manufacture controlled substances in Active Pharmaceutical Ingredient (API) form. The company distributes the manufactured APIs in bulk to its customers. The company plans to import the other listed controlled substances for internal reference standards use only. The comparisons of foreign reference standards to the company’s domestically manufacture API will allow the company to export domestically manufacture API to foreign markets. control laws at United Rolls’ iron foundry facility in Canton, Ohio. The Complaint alleges violations of recordkeeping and reporting requirements, as well as failure to meet requirements for the control of particulate matter emissions from United Rolls’ facility. The proposed Consent Decree would require United Rolls to perform emissions testing, upgrade an air pollution control monitoring system, and take other steps to control air pollutant emissions from its Canton facility. United Rolls also would pay a total of $310,000 in civil penalties (with $186,000 payable to the United States and $124,000 payable to the State). The publication of this notice opens a period for public comment on the proposed Consent Decree. Comments should be addressed to the Acting Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States and the State of Ohio v. United Rolls Inc., D.J. Ref. No. 90–5–2–1– 10704. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail: To submit comments: Send them to: By email ....... pubcomment-ees.enrd@ usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. By mail ......... Dated: October 31, 2017. Demetra Ashley, Acting Assistant Administrator. During the public comment period, the proposed Consent Decree may be BILLING CODE 4410–09–P examined and downloaded at this Justice Department Web site: https:// www.justice.gov/enrd/consent-decrees. DEPARTMENT OF JUSTICE We will provide a paper copy of the Consent Decree upon written request Notice of Lodging of Proposed and payment of reproduction costs. Consent Decree Under the Clean Air Please mail your request and payment Act to: Consent Decree Library, U.S. DOJ— On October 27, 2017, the Department ENRD, P.O. Box 7611, Washington, DC of Justice lodged a proposed Consent 20044–7611. Decree with the United States District Please enclose a check or money order Court for the Northern District of Ohio for $16.25 (25 cents per page in the lawsuit entitled United States and reproduction cost) payable to the United the State of Ohio v. United Rolls Inc., States Treasury. Civil Action No. 5:17–cv–02278. The United States and the State of Randall M. Stone, Ohio filed a Complaint seeking civil Acting Assistant Section Chief, penalties and injunctive relief from Environmental Enforcement Section, Defendant United Rolls Inc. for alleged Environment and Natural Resources Division. violations of the Clean Air Act, 42 [FR Doc. 2017–23915 Filed 11–2–17; 8:45 am] U.S.C. 7401–7671q, and corresponding BILLING CODE 4410–15–P provisions of Ohio’s air pollution [FR Doc. 2017–24012 Filed 11–2–17; 8:45 am] PO 00000 Frm 00089 Fmt 4703 Sfmt 9990 E:\FR\FM\03NON1.SGM 03NON1

Agencies

[Federal Register Volume 82, Number 212 (Friday, November 3, 2017)]
[Notices]
[Pages 51293-51298]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24009]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-470F]


Final Adjusted Aggregate Production Quotas for Schedule I and II 
Controlled Substances and Assessment of Annual Needs for the List I 
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017

AGENCY: Drug Enforcement Administration (DEA), Department of Justice 
(DOJ).

ACTION: Final order.

-----------------------------------------------------------------------

SUMMARY: This final order establishes the final adjusted 2017 aggregate 
production quotas for controlled substances in schedules I and II of 
the Controlled Substances Act and the assessment of annual needs for 
the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine.

DATES: This order is applicable November 3, 2017.

FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control 
Division, Drug Enforcement Administration, 8701 Morrissette Drive, 
Springfield, VA 22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION: 

Legal Authority

    Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) 
requires the Attorney General to establish aggregate production quotas 
for each basic class of controlled substances listed in schedules I and 
II and for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine. The Attorney General has delegated this function 
to the Administrator of the Drug Enforcement Administration (DEA) 
pursuant to 28 CFR 0.100.

Background

    The DEA published the 2017 established aggregate production quotas 
for controlled substances in schedules I and II and for the assessment 
of annual needs for the list I chemicals ephedrine, pseudoephedrine, 
and phenylpropanolamine in the Federal Register on October 5, 2016. 81 
FR 69079. This notice stated that the

[[Page 51294]]

Administrator would adjust, as needed, the established aggregate 
production quotas in 2017 in accordance with 21 CFR 1303.13 and 21 CFR 
1315.13. The 2017 proposed adjusted aggregate production quotas for 
controlled substances in schedules I and II and assessment of annual 
needs for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine were subsequently published in the Federal Register 
on August 4, 2017, (82 FR 36449) in consideration of the outlined 
criteria. All interested persons were invited to comment on or object 
to the proposed adjusted aggregate production quotas and assessment of 
annual needs on or before September 5, 2017.

Comments Received

    Three DEA-registered entities submitted timely comments regarding a 
total of eleven schedule I and II controlled substances. Comments 
received proposed that the aggregate production quotas for amphetamine 
(for conversion), dihydrocodeine, diphenoxylate (for sale), heroin, 
levorphanol, lisdexamfetmine, methadone intermediate, noroxymorphone 
(for conversion), oripavine, oxycodone (for sale), and oxymorphone (for 
conversion) were insufficient to provide for the estimated medical, 
scientific, research, and industrial needs of the United States, for 
export requirements, and for the establishment and maintenance of 
reserve stocks. The DEA received 43 comments from non-DEA registered 
entities in response to the DEA's August 4, 2017, press release for the 
proposed 2018 aggregate production quotas. The majority of these 
commenters expressed concerns about the 20 percent decrease to the 
production quotas of controlled substances. The DEA also received two 
comments from non-DEA registered entities suggesting that the 
rescheduling of marihuana would drastically reduce opioid use, misuse, 
and addiction. These 45 comments addressed issues that were outside the 
scope of this final order, and therefore are not relevant to the 
analysis involved in finalizing the 2017 aggregate production quotas.
    The DEA received no comments from DEA-registered or non-DEA 
registered entities for previously established values of the 2017 
assessment of annual needs for ephedrine, pseudoephedrine, and 
phenylpropanolamine.

Analysis for Final Adjusted 2017 Aggregate Production Quotas and 
Assessment of Annual Needs

    In determining the final adjusted 2017 aggregate production quotas 
and assessment of annual needs, the DEA has taken into consideration 
the above comments that are specifically relevant to this Final Order 
for calendar year 2017 along with the factors set forth in 21 CFR 
1303.13 and 21 CFR 1315.13 in accordance with 21 U.S.C. 826(a), and 
other relevant factors including the 2016 year-end inventories, initial 
2017 manufacturing and import quotas, 2017 export requirements, actual 
and projected 2017 sales, research and product development 
requirements, and additional applications received. Based on all of the 
above, the Administrator is adjusting the 2017 aggregate production 
quotas and assessment of annual needs for 4-Anilino-N-Phenethyl-4-
Piperidine (ANPP), dihydrocodeine, ephedrine (for sale), fentanyl, 
hydrocodone (for sale), meperidine, methadone intermediate, morphine 
(for sale), opium (tincture), Oripavine, oxycodone (for sale), 
Oxymorphone (for conversion), Oxymorphone (for sale), 
phenylpropanolamine (for conversion), phenylpropanolamine (for sale), 
pseudoephedrine (for sale), tapentadol, and thiafentanil. This final 
order reflects those adjustments.
    Regarding diphenoxylate (for sale), heroin, levorphanol, and 
noroxymorphone (for conversion) the Administrator hereby determines 
that the proposed adjusted 2017 aggregate production quotas and 
assessment of annual needs for these substances and list I chemicals as 
published on August 4, 2017, (82 FR 36449) are sufficient to meet the 
current 2017 estimated medical, scientific, research, and industrial 
needs of the United States and to provide for adequate reserve stock. 
This final order establishes these aggregate production quotas at the 
same amounts as proposed.
    Pursuant to the above, the Administrator hereby finalizes the 2017 
aggregate production quotas for the following schedule I and II 
controlled substances and the 2017 assessment of annual needs for the 
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 
expressed in grams of anhydrous acid or base, as follows:

------------------------------------------------------------------------
                                                          Final revised
                      Basic class                        2017 quotas (g)
------------------------------------------------------------------------
                               Schedule I
------------------------------------------------------------------------
1-(1-Phenylcyclohexyl)pyrrolidine......................               10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)......               30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).....               30
1-[1-(2-Thienyl)cyclohexyl]piperidine..................               15
1-Benzylpiperazine.....................................               25
1-Methyl-4-phenyl-4-propionoxypiperidine...............                2
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).......               30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)......               30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)......               30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)....               30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)...............               30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-                                 25
 methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B;
 Cimbi-36).............................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)......               30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-                                25
 methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C;
 Cimbi-82).............................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)........               30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-                                  30
 methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
 Cimbi-5)..............................................
2,5-Dimethoxy-4-ethylamphetamine (DOET)................               25
2,5-Dimethoxy-4-n-propylthiophenethylamine.............               25
2,5-Dimethoxyamphetamine...............................               25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-                30
 2)....................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-              30
 T-4)..................................................
3,4,5-Trimethoxyamphetamine............................               25
3,4-Methylenedioxyamphetamine (MDA)....................               55

[[Page 51295]]

 
3,4-Methylenedioxymethamphetamine (MDMA)...............               50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)...........               40
3,4-Methylenedioxy-N-methylcathinone (methylone).......               40
3,4-Methylenedioxypyrovalerone (MDPV)..................               35
3-FMC; 3-Fluoro-N-methylcathinone......................               25
3-Methylfentanyl.......................................               30
3-Methylthiofentanyl...................................               30
4-Bromo-2,5-dimethoxyamphetamine (DOB).................               25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).............               25
4-Fluoroisobutyryl fentanyl............................               30
4-FMC; Flephedrone.....................................               25
4-MEC; 4-Methyl-N-ethylcathinone.......................               25
4-Methoxyamphetamine...................................              150
4-Methyl-2,5-dimethoxyamphetamine (DOM)................               25
4-Methylaminorex.......................................               25
4-Methyl-N-methylcathinone (mephedrone)................               45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP)....               25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-               50
 phenol................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-                40
 phenol (cannabicyclohexanol or CP-47,497 C8-homolog)..
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-              30
 indazole-3-carboxamido)-3,3-dimethylbutanoate)........
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-                   30
 carboxamido)-3-methylbutanoate).......................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-                        30
 fluoropentyl)-1H-indazole-3-carboxamide)..............
5-Fluoro-PB-22; 5F-PB-22...............................               20
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-                25
 yl](2,2,3,3-tetramethylcyclopropyl)methanone..........
5-Methoxy-3,4-methylenedioxyamphetamine................               25
5-Methoxy-N,N-diisopropyltryptamine....................               25
5-Methoxy-N,N-dimethyltryptamine.......................               25
AB-CHMINACA............................................               30
AB-FUBINACA............................................               50
AB-PINACA..............................................               30
Acetyl Fentanyl........................................              100
Acetyl-alpha-methylfentanyl............................               30
Acetyldihydrocodeine...................................               30
Acetylmethadol.........................................                2
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-               30
 1-(4-fluorobenzyl)-1H-indazole-3-carboxamide).........
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-               50
 pentyl-1H-indazole-3-carboxamide).....................
AH-7921................................................               30
Allylprodine...........................................                2
Alphacetylmethadol.....................................                2
alpha-Ethyltryptamine..................................               25
Alphameprodine.........................................                2
Alphamethadol..........................................                2
alpha-Methylfentanyl...................................               30
alpha-Methylthiofentanyl...............................               30
alpha-Methyltryptamine (AMT)...........................               25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)............               25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)...........               25
Aminorex...............................................               25
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-                25
 carboxamide)..........................................
Benzylmorphine.........................................               30
Betacetylmethadol......................................                2
beta-Hydroxy-3-methylfentanyl..........................               30
beta-Hydroxyfentanyl...................................               30
beta-Hydroxythiofentanyl...............................               30
Betameprodine..........................................                2
Betamethadol...........................................                4
Betaprodine............................................                2
Bufotenine.............................................                3
Butylone...............................................               25
Butyryl Fentanyl.......................................               30
Cathinone..............................................               24
Codeine Methylbromide..................................               30
Codeine-N-oxide........................................              330
Desomorphine...........................................               25
Diethyltryptamine......................................               25
Difenoxin..............................................            8,750
Dihydromorphine........................................        1,566,000
Dimethyltryptamine.....................................               35
Dipipanone.............................................                5
Etorphine..............................................               30
Fenethylline...........................................               30
Furanyl Fentanyl.......................................               30

[[Page 51296]]

 
gamma-Hydroxybutyric acid..............................       56,200,000
Heroin.................................................               45
Hydromorphinol.........................................                2
Hydroxypethidine.......................................                2
Ibogaine...............................................               30
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole).....               35
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)................               45
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)................               45
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)....               30
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)......               30
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-                             35
 naphthoyl)indole).....................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)......               30
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).....               30
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)......               30
Lysergic acid diethylamide (LSD).......................               40
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-                30
 oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
 carboxamide)..........................................
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-                                30
 (cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
 dimethylbutanoate)....................................
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-              30
 3-carboxamido)-3,3-dimethylbutanoate).................
Marihuana..............................................          472,000
Mecloqualone...........................................               30
Mescaline..............................................               25
Methaqualone...........................................               60
Methcathinone..........................................               25
Methyldesorphine.......................................                5
Methyldihydromorphine..................................                2
Morphine methylbromide.................................                5
Morphine methylsulfonate...............................                5
Morphine-N-oxide.......................................              350
N,N-Dimethylamphetamine................................               25
Naphyrone..............................................               25
N-Ethyl-1-phenylcyclohexylamine........................                5
N-Ethylamphetamine.....................................               24
N-Hydroxy-3,4-methylenedioxyamphetamine................               24
Noracymethadol.........................................                2
Norlevorphanol.........................................               55
Normethadone...........................................                2
Normorphine............................................               40
para-Fluorofentanyl....................................               25
Parahexyl..............................................                5
PB-22; QUPIC...........................................               20
Pentedrone.............................................               25
Pentylone..............................................               25
Phenomorphan...........................................                2
Pholcodine.............................................                5
Psilocybin.............................................               30
Psilocyn...............................................               50
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-                              45
 methoxyphenylacetyl)indole)...........................
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-                             30
 benzoyl]indole).......................................
Tetrahydrocannabinols..................................          409,000
Thiofentanil...........................................               25
THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-                          30
 yl](naphthalen-1-yl)methanone)........................
Tilidine...............................................               25
Trimeperidine..........................................                2
U-47700................................................               30
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-                              25
 tetramethylcyclopropyl)methanone......................
------------------------------------------------------------------------
                               Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................                4
1-Piperidinocyclohexanecarbonitrile....................                4
4-Anilino-N-phenethyl-4-piperidine (ANPP)..............        1,050,000
Alfentanil.............................................            4,200
Alphaprodine...........................................                2
Amobarbital............................................           20,100
Amphetamine (for conversion)...........................       12,000,000
Amphetamine (for sale).................................       42,400,000
Carfentanil............................................               20
Cocaine................................................          103,400
Codeine (for conversion)...............................       40,000,000
Codeine (for sale).....................................       45,000,000
Dextropropoxyphene.....................................               35

[[Page 51297]]

 
Dihydrocodeine.........................................          360,000
Dihydroetorphine.......................................                2
Diphenoxylate (for conversion).........................           15,000
Diphenoxylate (for sale)...............................        1,110,000
Ecgonine...............................................           99,000
Ethylmorphine..........................................               30
Etorphine Hydrochloride................................               32
Fentanyl...............................................        1,350,000
Glutethimide...........................................                2
Hydrocodone (for conversion)...........................          122,000
Hydrocodone (for sale).................................       51,900,000
Hydromorphone..........................................        5,140,800
Isomethadone...........................................               30
Levo-alphacetylmethadol (LAAM).........................                5
Levomethorphan.........................................               30
Levorphanol............................................           12,900
Lisdexamfetamine.......................................       19,000,000
Meperidine.............................................        2,904,000
Meperidine Intermediate-A..............................                5
Meperidine Intermediate-B..............................               30
Meperidine Intermediate-C..............................                5
Metazocine.............................................               15
Methadone (for sale)...................................       23,700,000
Methadone Intermediate.................................       28,700,000
Methamphetamine........................................        1,539,100
------------------------------------------------------------------------
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
 prescription product; 600,000 grams for methamphetamine mostly for
 conversion to a schedule III product; and 39,100 grams for
 methamphetamine (for sale)]............................................
------------------------------------------------------------------------
Methylphenidate........................................       73,000,000
Morphine (for conversion)..............................       27,300,000
Morphine (for sale)....................................       35,000,000
Nabilone...............................................           19,000
Noroxymorphone (for conversion)........................       17,700,000
Noroxymorphone (for sale)..............................          400,000
Opium (powder).........................................           90,000
Opium (tincture).......................................          500,000
Oripavine..............................................       28,900,000
Oxycodone (for conversion).............................        2,610,000
Oxycodone (for sale)...................................      101,500,000
Oxymorphone (for conversion)...........................       23,000,000
Oxymorphone (for sale).................................        3,600,000
Pentobarbital..........................................       27,500,000
Phenazocine............................................                5
Phencyclidine..........................................               35
Phenmetrazine..........................................               25
Phenylacetone..........................................               40
Racemethorphan.........................................                5
Racemorphan............................................                5
Remifentanil...........................................            3,000
Secobarbital...........................................          172,002
Sufentanil.............................................            4,000
Tapentadol.............................................       18,600,000
Thiafentanil...........................................               30
Thebaine...............................................      100,000,000
------------------------------------------------------------------------
                            List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion).............................           50,000
Ephedrine (for sale)...................................        4,810,000
Phenylpropanolamine (for conversion)...................       13,600,000
Phenylpropanolamine (for sale).........................        7,000,000
Pseudoephedrine (for conversion).......................               40
Pseudoephedrine (for sale).............................      186,000,000
------------------------------------------------------------------------


[[Page 51298]]

    Aggregate production quotas for all other schedule I and II 
controlled substances included in 21 CFR 1308.11 and 1308.12 remain at 
zero.

    Dated: October 27, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017-24009 Filed 11-2-17; 8:45 am]
BILLING CODE 4410-09-P